Child Pneumococcal Serotype Epidemiology In Greece

NCT01111214

Last updated date
Study Location
Agia Sophia Children's Hospital
Athens, Attiki, 115 27, Greece
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-14
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Children aged 14 years old or less.

- Hospitalized in a participating healthcare facility with an IPD.

- IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Children > 14 years of age


- Unconfirmed IPD

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants NCT04379713
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal DiseaseSerotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year. NCT01564771
  1. Athens, Attiki
  2. Alexandroupoli, Evros
  3. Alexandroupoli,
  4. Athens,
  5. Athens,
  6. Athens,
  7. Athens,
  8. Athens,
  9. Athens,
  10. Athens,
  11. Athens,
  12. Athens,
  13. Athens,
  14. Athens,
  15. Athens,
  16. Athens,
  17. Athens,
  18. Athnens,
  19. Kavala,
  20. Kavala,
  21. Larissa,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pneumococcal DiseaseChild Pneumococcal Serotype Epidemiology In Greece NCT01111214
  1. Athens, Attiki
  2. Alexandroupoli,
  3. Herakleion,
  4. Herakleion,
  5. Ioannina,
  6. Larissa,
  7. Thessaloniki,
  8. Thessaloniki,
  9. Trikala,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Child Pneumococcal Serotype Epidemiology In Greece
Official Title Incidence And Serotypes Of Invasive Pneumococcal Disease, After The Introduction Of The Heptavalent Conjugated Vaccine In Greece
Brief Summary

Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program.

The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.

Detailed Description open label, one group Purposive sampling of hospitalized children ?14 years of age with confirmed IPD
Study Type Observational
Study Design Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Hospitalized children in participating centers
Condition Pneumococcal Disease
Intervention Other: no intervention
There is no intervention. This is a non interventional study.
Study Groups/Cohorts group 1
Hospitalized children ?14 years of age with invasive pneumococcal disease
Intervention: Other: no intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: December 20, 2012)
457
Original Estimated Enrollment
 (submitted: April 26, 2010)
300
Actual Study Completion Date November 2012
Actual Primary Completion Date November 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Children aged 14 years old or less.
  • Hospitalized in a participating healthcare facility with an IPD.
  • IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.

Exclusion Criteria:

  • Children > 14 years of age
  • Unconfirmed IPD
Sex/Gender
Sexes Eligible for Study:All
Ages up to 14 Years   (Child)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Greece
Removed Location Countries  
 
Administrative Information
NCT Number NCT01111214
Other Study ID Numbers 0887X1-4434
B1841010
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2013